GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Fluoxetine daily capsules (adults)

Prozac

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Fluoxetine daily capsules (adults) - selected U.S. labeling

Product / population
Adult major depressive disorder; daily oral immediate-release fluoxetine capsules. Excludes weekly delayed-release products and olanzapine combinations.
Renal measure
Qualitative renal guidance, supported by a small dialysis pharmacokinetic study; no CrCl dose table.
Labeled basic dosing

Start 20 mg orally each morning. Consider escalation after several weeks when response is insufficient. Doses above 20 mg/day may be once daily or divided morning/noon; maximum 80 mg/day.

Renal information and dialysis

The label does not routinely require a lower dose or longer interval for renal impairment. In 12 dialysis patients, 20 mg/day produced parent/metabolite concentrations comparable to normal renal function; possible accumulation of other renally eliminated metabolites is acknowledged.

Selected warnings and limits

Review suicidality, serotonin syndrome and interacting medicines. Delayed steady state and the prolonged elimination of fluoxetine/norfluoxetine matter when adjusting or switching treatment.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8609ed02-0b30-4c82-bab1-4d51d92ec224

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Fluoxetine daily capsules (adults) - selected U.S. labeling

Adult major depressive disorder; daily oral immediate-release fluoxetine capsules. Excludes weekly delayed-release products and olanzapine combinations.

Renal method: Qualitative renal guidance, supported by a small dialysis pharmacokinetic study; no CrCl dose table.
Retrieved: 2026-09-05

Handbook

Renal Drug Handbook, fifth edition - Fluoxetine daily capsules (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Retrieved: 2026-09-05

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

Fluoxetine daily capsules (adults) - selected U.S. labeling

Adult major depressive disorder; daily oral immediate-release fluoxetine capsules. Excludes weekly delayed-release products and olanzapine combinations.

Method: Qualitative renal guidance, supported by a small dialysis pharmacokinetic study; no CrCl dose table.

Handbook source

Renal Drug Handbook, fifth edition - Fluoxetine daily capsules (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8609ed02-0b30-4c82-bab1-4d51d92ec224

Product and population scope

Adult major depressive disorder; daily oral immediate-release fluoxetine capsules. Excludes weekly delayed-release products and olanzapine combinations.

RDM31-fluoxetine-ir-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Fluoxetine daily capsules (adults) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult major depressive disorder; daily oral immediate-release fluoxetine capsules. Excludes weekly delayed-release products and olanzapine combinations.

Renal method: Qualitative renal guidance, supported by a small dialysis pharmacokinetic study; no CrCl dose table.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

Start 20 mg orally each morning. Consider escalation after several weeks when response is insufficient. Doses above 20 mg/day may be once daily or divided morning/noon; maximum 80 mg/day.

RDM31-fluoxetine-ir-label-dose · Source locator: 2.1 Major Depressive Disorder

Renal information and dialysis

The label does not routinely require a lower dose or longer interval for renal impairment. In 12 dialysis patients, 20 mg/day produced parent/metabolite concentrations comparable to normal renal function; possible accumulation of other renally eliminated metabolites is acknowledged.

RDM31-fluoxetine-ir-label-renal · Source locator: 12.3 Renal Disease

Selected warnings and limits

Review suicidality, serotonin syndrome and interacting medicines. Delayed steady state and the prolonged elimination of fluoxetine/norfluoxetine matter when adjusting or switching treatment.

RDM31-fluoxetine-ir-label-limits · Source locator: Boxed warning; 5; 12.3 Accumulation and slow elimination

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8609ed02-0b30-4c82-bab1-4d51d92ec224
Retrieved
2026-09-05
DailyMed Set ID
8609ed02-0b30-4c82-bab1-4d51d92ec224
Renal-function method
Qualitative renal guidance, supported by a small dialysis pharmacokinetic study; no CrCl dose table.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
bca97575c4f0863431aa70237754e8dbc89699e8fdd9db484990d2d6a2852f5b
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition - Fluoxetine daily capsules (adults)

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date: Fifth edition, 2019
Retrieved: 2026-09-05

Historical source, separately displayed. Renal tables were read with page-image inspection.

Historical renal and dialysis observations

The book retains ordinary dosing at 20-50 and 10-20 mL/min, but below 10 suggests low doses or alternate-day dosing with response-guided escalation. It describes little dialysis removal and applies the below-10 approach to intermittent and peritoneal modalities; continuous therapy uses its 10-20 band.

RDM31-fluoxetine-ir-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information

Source-specific limits

The historical below-10 advice is more conservative than the selected label. These are alternative source positions, not a combined schedule.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 441-442; PDF page(s) 460,461
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date/version
Fifth edition, 2019
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8609ed02-0b30-4c82-bab1-4d51d92ec224
Hash meaning
SHA-256 identifies the local paraphrase; the source PDF is not redistributed.
Local summary SHA-256
5b34a590007480e16e6ed5c3bea9a723a10be36f1ee67bc7edc1534f43d448c0

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8609ed02-0b30-4c82-bab1-4d51d92ec224
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
7e6181ebb87a6ac9aee84969eb148f8e183505eeb639a883531a6c6f258bfe1e
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report